DSIP Benefits: Claims vs What Studies Show
Benefits people claim for DSIP, set against what published studies measured, and where no study exists.
- Strongest evidence
- Human RCT
- Human / animal studies
- 9 / 4
- in our evidence file (PubMed search, 11 Oct 2026)
- FDA status
- Not approved
- Off Category 2, 15 Apr 2026
Claimed benefits and what studies show
Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Claim | Best evidence | Studies (human / animal) | What was measured | Page |
|---|---|---|---|---|
| Sleep | Human RCT evidence, 4 of 4 | 8 / 1 | Anaesthetic depth (BIS); Sleep efficiency and latency; Overall therapeutic benefit | Evidence for sleep |
| Brain health | Human RCT evidence, 4 of 4 | 1 / 1 | Daytime alertness; Seizures | None |
| Growth hormone | Human RCT evidence, 4 of 4 | 1 / 0 | Growth hormone and prolactin | Evidence for growth hormone |
Strongest study per claim: Sleep, European journal of anaesthesiology 2009, PMID 19142086; Brain health, European neurology 1987, PMID 3622582; Growth hormone, Psychoneuroendocrinology 1993, PMID 8475226.
What the studies measured
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Anaesthetic depth (BIS) | DSIP lightened anaesthetic depth (higher BIS, less delta rhythm) and raised heart rate; the opposite of the hypnotic effect predicted. | Human RCTn = 24 | European journal of anaesthesiology 2009, PMID 19142086 |
| Growth hormone and prolactin | DSIP did not change growth hormone or prolactin secretion. | Human controlled trialn = 8 | Psychoneuroendocrinology 1993, PMID 8475226 |
| Sleep efficiency and latency | Polysomnography showed higher sleep efficiency and shorter sleep latency with DSIP than placebo. | Human RCTn = 16 | Neuropsychobiology 1992, PMID 1299794 |
| Overall therapeutic benefit | The authors concluded short-term DSIP is unlikely to be of major therapeutic benefit in chronic insomnia; subjective sleep quality did not change. | Human RCTn = 16 | Neuropsychobiology 1992, PMID 1299794 |
| Sleep time and clinical significance | Sleep improved slightly under DSIP but the authors judged it of little clinical significance. | Human controlled trial | International journal of clinical pharmacology research 1987, PMID 3583493 |
| Night sleep | DSIP substantially improved night sleep with the first and with repeated doses. | Human controlled trialn = 14 | European neurology 1987, PMID 3622582 |
| Daytime alertness | Daytime alertness and performance increased significantly. | Human controlled trialn = 14 | European neurology 1987, PMID 3622582 |
| Sleep normalisation in insomniacs | Four consecutive injections normalised disturbed sleep in insomniacs in this early series. | Human controlled trial | Neuropsychobiology 1983, PMID 6689058 |
| Latency and duration | Sleep induction took about 1 hour to start and effects lasted up to 20 hours. | Human controlled trial | Neuropsychobiology 1983, PMID 6689058 |
| Total sleep time | Median total sleep time rose by 59% in the 130 minutes after a morning DSIP infusion versus placebo. | Human controlled trialn = 6 | International journal of clinical pharmacology, therapy, and toxicology 1981, PMID 6895513 |
| Plasma DSIP-like immunoreactivity | Endogenous DSIP-like immunoreactivity did not differ significantly between groups. | Human observationaln = 30 | Peptides 1995, PMID 8532601 |
| Sleep duration and quality | Longer, less interrupted sleep with no day-time sedation or other side effects in 6 insomniacs after a single dose. | Human uncontrolled trialn = 6 | Experientia 1981, PMID 7028502 |
| Sleep promotion by DSIP fusion peptide | A DSIP fusion peptide restored neurotransmitter imbalance better than DSIP alone and may enhance sleep in insomniac mice. | Animal · mouse (not a human result) | Frontiers in pharmacology 2024, PMID 39444618 |
| Seizures | DSIP and DSIP-12 reduced seizure incidence, grade and duration in rats and increased delta and theta EEG power. | Animal · rat (not a human result) | Seizure 2005, PMID 15911358 |
| CSF penetration | DSIP and analogs significantly crossed the blood-CSF barrier in dogs, depending on plasma level, half-life and lipophilicity. | Animal · dog (not a human result) | Brain research bulletin 1986, PMID 3768731 |
| Clearance and half-life | DSIP disappeared rapidly from dog plasma, with a mean half-life of 4.0 +/- 0.7 min. | Animal · dog, monkey and rat (not a human result) | Neuroendocrinology 1984, PMID 6379493 |
The sleep claim: small human studies, mostly intravenous, with mixed verdicts
In chronic insomnia patients, DSIP gave weak effects on sleep efficiency and latency, and the authors concluded short-term treatment is unlikely to be of major benefit.[3]
A double-blind crossover study in insomniacs found that the sleep improvement under DSIP was of little clinical significance.[4]
A placebo-controlled study in severe chronic insomniacs reported better night sleep and daytime alertness over repeated nights.[5]
The first human study, in normal volunteers, reported a rise in total sleep time versus placebo within a 130-minute window after infusion.[7]
A small case series of chronic insomniacs reported longer sleep, with the sleep-promoting effect only in the second hour and a slight arousing effect in the first.[9]
The alertness and cognition claim
One human report states DSIP raised daytime alertness and performance in insomniacs.[5]
A multi-study review reports higher alertness and better performance in the awake state, and flags that other psychiatric uses remained to be explored.[6]
During anaesthesia, however, DSIP reduced delta rhythm and raised bispectral index, which the authors read as lightening of anaesthetic depth.[1]
The growth hormone claim has a negative human result
In healthy women, DSIP infusions changed neither growth hormone nor prolactin secretion.[2]
A study of plasma DSIP-like immunoreactivity found no group differences between sleep apnea, narcolepsy and normal controls, so it is not a disease marker.[8]
How much human evidence exists
A PubMed search on 2 Oct 2026 for DSIP terms combined with humans, patients, insomnia or volunteers returned 108 records out of 444 for the peptide overall; a narrower controlled-trial query returned 27.
Calculated from date 2026-10-02; human query count 108; controlled query count 27; total peptide records 444; source web/src/data/evidence/dsip.json searches. Formula: shares = 108 / 444 and 27 / 444
More on DSIP
Common questions
Is DSIP proven to work?
The strongest study we summarise for DSIP is human rct evidence, among 13 studies. A trial result is not an approval; see the legal status.
What is DSIP peptide used for?
The cached human studies tested it for chronic insomnia, with doses given in the vein.[4]
What does DSIP do?
In the earliest volunteer study the peptide was well tolerated, with no side effects observed, but no classic sedation either.[7]
More on DSIP
Sources
- 1Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia.European journal of anaesthesiology · 2009PMID 19142086Accessed 2 Oct 2026
- 2Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women.Psychoneuroendocrinology · 1993PMID 8475226Accessed 2 Oct 2026
- 3Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.Neuropsychobiology · 1992PMID 1299794Accessed 2 Oct 2026
- 4Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs.International journal of clinical pharmacology research · 1987PMID 3583493Accessed 2 Oct 2026
- 5Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia.European neurology · 1987PMID 3622582Accessed 2 Oct 2026
- 6Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep.Neuropsychobiology · 1983PMID 6689058Accessed 2 Oct 2026
- 7Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior.International journal of clinical pharmacology, therapy, and toxicology · 1981PMID 6895513Accessed 2 Oct 2026
- 8Delta sleep-inducing peptide in normal humans and in patients with sleep apnea and narcolepsy.Peptides · 1995PMID 8532601Accessed 2 Oct 2026
- 9The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep.Experientia · 1981PMID 7028502Accessed 2 Oct 2026
- 10Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models.Frontiers in pharmacology · 2024PMID 39444618Accessed 2 Oct 2026
- 11Antiepileptic activity of delta sleep-inducing peptide and its analogue in metaphit-provoked seizures in rats.Seizure · 2005PMID 15911358Accessed 2 Oct 2026
- 12Entry of DSIP peptides into dog CSF: role of physicochemical and pharmacokinetic parameters.Brain research bulletin · 1986PMID 3768731Accessed 2 Oct 2026
- 13Development of an enzyme immunoassay for delta sleep-inducing peptide (DSIP) and its use in the determination of the metabolic clearance rate of DSIP administered to dogs.Neuroendocrinology · 1984PMID 6379493Accessed 2 Oct 2026
- 14PubMed search: ("delta sleep-inducing peptide"[tiab] OR emideltide[tiab] OR (DSIP[tiab] AND (peptide*[tiab] OR sleep*[tiab]))) (444 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: ("delta sleep-inducing peptide"[tiab] OR emideltide[tiab] OR (DSIP[tiab] AND (peptide*[tiab] OR sleep*[tiab]))) AND (humans[mh] OR patients[tiab] OR insomnia[tiab] OR volunteers[tiab]) (108 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16PubMed search: ("delta sleep-inducing peptide"[tiab] OR emideltide[tiab] OR (DSIP[tiab] AND (peptide*[tiab] OR sleep*[tiab]))) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 17PubMed search: ("delta sleep-inducing peptide"[tiab] OR emideltide[tiab]) AND (insomnia[tiab] OR "double-blind"[tiab] OR "clinical trial"[pt] OR "randomized controlled trial"[pt] OR "controlled clinical trial"[pt]) (27 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 18PubMed search: ("delta sleep-inducing peptide"[tiab] OR emideltide[tiab] OR DSIP[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
Found an error? Report a correction.